Status: Not yet recruiting
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yu jirenUpdated: Aug 1, 2023Locations: 8
Eligibility criteria
Voluntary participation in the clinical study; fully understands and is informed... [+17]
HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplificat... [+16]